Topic

Mike Straus is a freelance writer based in British Columbia, Canada. His work has appeared in 

Nutritional Outlook, Hoist, and Massage Therapy Canada

Articles

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

2023 Pipeline Report: Testing the Limits

Webcasts

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET


Expand Marketing Reach and Enhance Commercial Ops With Real-Time Patient Data

Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

The Manufacturing Edge on Path to Market

 and can be reached at mhollan@mjhlifesciences.com.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants 

Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.

More Than a Name: Vyvgart

Elaine Quilici is a contributing editor of 

Use against pair of pathways could pave way for standout in stocked eye disease market.

Fighting Vision Loss: Vabysmo

Michael Christel is the group managing editor of 

Pharmaceutical Executive, Pharmaceutical Commerce

 and can be reached at mchristel@mjhlifesciences.com.

Tapping the potential of new market mindset in insomnia—delivering a quality next day.

A Sleeping Giant?: Quviviq 

’s 2022 summer editorial intern and is now an Assistant Editor for 

Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.

Next-level Efficacy: Mounjaro

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

More favorable administration, reimbursement could separate latest PCSK9 entrant.

R&D/Clinical Trials